Bluejay Diagnostics, Inc. Capital Expenditures
Bluejay Diagnostics, Inc. (BJDX) reported Capital Expenditures of $161.76 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $142.77K.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $18.99K.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $1.13K, a 98.72% decline year-over-year.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $227.00, a 99.70% decline year-over-year.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $173.74K, a 43.37% decline from fiscal 2024.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $306.78K, a 56.43% decline from fiscal 2023.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $704.17K, a 41.28% decline from fiscal 2022.
- Bluejay Diagnostics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $1.20M, a 4908.02% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $161.76K 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | $18.99K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $173.74K 10-K · filed 2026-03-06 | |||
| 2024-12-31 | $1.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.35K derived: sum of 2 quarters · filed 2026-03-06 | $271.35K derived: sum of 3 quarters · filed 2026-03-06 | $306.78K 10-K · filed 2026-03-06 |
| 2024-09-30 | $227.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $270.23K derived: sum of 2 quarters · filed 2025-11-07 | $305.66K 10-Q · filed 2025-11-07 | $393.55K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $270.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $305.43K 10-Q · filed 2025-08-07 | $393.32K derived: sum of 3 quarters · filed 2025-08-07 | $467.82K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $35.43K 10-Q · filed 2025-05-13 | $123.33K derived: sum of 2 quarters · filed 2025-05-13 | $197.82K derived: sum of 3 quarters · filed 2025-05-13 | $398.93K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $87.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $162.39K derived: sum of 2 quarters · filed 2025-03-31 | $363.50K derived: sum of 3 quarters · filed 2025-03-31 | $704.17K 10-K · filed 2025-03-31 |
| 2023-09-30 | $74.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $275.60K derived: sum of 2 quarters · filed 2024-11-07 | $616.27K 10-Q · filed 2024-11-07 | $854.48K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $201.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $541.77K 10-Q · filed 2024-08-14 | $779.98K derived: sum of 3 quarters · filed 2024-08-14 | $1.57M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $340.67K 10-Q · filed 2024-05-15 | $578.88K derived: sum of 2 quarters · filed 2024-05-15 | $1.37M derived: sum of 3 quarters · filed 2024-05-15 | $1.49M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $238.21K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.03M derived: sum of 2 quarters · filed 2024-03-28 | $1.15M derived: sum of 3 quarters · filed 2024-03-28 | $1.20M 10-K · filed 2024-03-28 |
| 2022-09-30 | $791.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $914.72K derived: sum of 2 quarters · filed 2023-11-09 | $961.06K 10-Q · filed 2023-11-09 | $978.80K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $123.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $169.60K 10-Q · filed 2023-08-14 | $187.33K derived: sum of 3 quarters · filed 2023-08-14 | $191.61K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $46.35K 10-Q · filed 2023-05-11 | $64.08K derived: sum of 2 quarters · filed 2023-05-11 | $68.36K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $17.73K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $22.01K derived: sum of 2 quarters · filed 2023-03-20 | $23.95K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $4.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.21K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $1.93K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |